高级检索
中华结核和呼吸杂志
期刊首页
过刊列表
高级检索
稿件发表
• 综述 •
ENGLISH ABSTRACT
特发性炎性肌病相关性间质性肺疾病的诊治进展
黄慧
邵池
李珊
宋新宇
徐作军
作者及单位信息
·
DOI： 10.3760/cma.j.issn.1001-0939.2017.08.017
Update of idiopathic inflammatory myopathy associated interstitial lung disease
Huang Hui
Shao Chi
Li Shan
Authors Info & Affiliations
Huang Hui
Shao Chi
Li Shan
·
DOI： 10.3760/cma.j.issn.1001-0939.2017.08.017
0
0
0
0
0
0
PDF下载
APP内阅读
摘要

特发性炎性肌病(idiopathic inflammatory myopathy，IIM)包括多肌炎、皮肌炎、包涵体肌炎以及免疫介导的坏死性肌病；近年来随着肌炎特异性抗体(myositis-specific antibodies，MSA)的提出和临床应用以及对间质性肺疾病的研究进展，逐渐对抗合成酶综合征(antisynthetase syndrome，ASS)和无肌病皮肌炎(clinically amyopathic dermatomyositis, CADM)等特殊亚型有了进一步认识 [ 1 , 2 ] 。20%～78%的IIM患者合并间质性肺疾病，以ASS、CADM以及传统的多肌炎和皮肌炎患者多见，严重影响这类患者的预后 [ 3 , 4 ] 。为提高IIM相关性间质性肺疾病(IIM associated interstitial lung disease, IIM-ILD)的诊疗水平，现对近3年来IIM-ILD的诊治进展综述如下。

引用本文

黄慧,邵池,李珊,等. 特发性炎性肌病相关性间质性肺疾病的诊治进展[J]. 中华结核和呼吸杂志,2017,40(8)：625-628.

DOI:10.3760/cma.j.issn.1001-0939.2017.08.017

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

特发性炎性肌病(idiopathic inflammatory myopathy，IIM)包括多肌炎、皮肌炎、包涵体肌炎以及免疫介导的坏死性肌病；近年来随着肌炎特异性抗体(myositis-specific antibodies，MSA)的提出和临床应用以及对间质性肺疾病的研究进展，逐渐对抗合成酶综合征(antisynthetase syndrome，ASS)和无肌病皮肌炎(clinically amyopathic dermatomyositis, CADM)等特殊亚型有了进一步认识 [ 1 , 2 ]。20%～78%的IIM患者合并间质性肺疾病，以ASS、CADM以及传统的多肌炎和皮肌炎患者多见，严重影响这类患者的预后 [ 3 , 4 ]。为提高IIM相关性间质性肺疾病(IIM associated interstitial lung disease, IIM-ILD)的诊疗水平，现对近3年来IIM-ILD的诊治进展综述如下。
参考文献
[1]
Tieu J , Lundberg IE , Limaye V . Idiopathic inflammatory myositis[J]．Best Pract Res Clin Rheumatol, 2016，30(1)：149-168. DOI: 10.1016/j.berh.2016.04.007 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Lundberg IE , Miller FW , Tjärnlund A ,et al. Diagnosis and classification of idiopathic inflammatory myopathies[J]．J Intern Med, 2016，280(1)：39-51. DOI: 10.1111/joim.12524 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Morisset J , Johnson C , Rich E ,et al. Management of Myositis-Related Interstitial Lung Disease[J]．Chest, 2016，150(5)：1118-1128. DOI: 10.1016/j.chest.2016.04.007 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Hallowell RW , Danoff SK . Interstitial lung disease associated with the idiopathic inflammatory myopathies and the antisynthetase syndrome: recent advances[J]．Curr Opin Rheumatol, 2014，26(6)：684-689. DOI: 10.1097/BOR.0000000000000104 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Yoshifuji H . Biomarkers and Autoantibodies of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies[J]．Clin Med Insights Circ Respir Pulm Med, 2015，9(Suppl 1)：141-146. DOI: 10.4137/CCRPM.S36748 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Nakashima R , Hosono Y , Mimori T . Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease[J]．Lupus, 2016，25(8)：925-933. DOI: 10.1177/0961203316651748 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Miller SA , Glassberg MK , Ascherman DP . Pulmonary complications of inflammatory myopathy[J]．Rheum Dis Clin North Am, 2015，41(2)：249-262. DOI: 10.1016/j.rdc.2014.12.006 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Lega JC , Reynaud Q , Belot A ,et al. Idiopathic inflammatory myopathies and the lung[J]．Eur Respir Rev, 2015，24(136)：216-238. DOI: 10.1183/16000617.00002015 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Chatterjee S , Prayson R , Farver C . Antisynthetase syndrome: not just an inflammatory myopathy[J]．Cleve Clin J Med, 2013，80(10)：655-666. DOI: 10.3949/ccjm.80a.12171 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Hervier B , Benveniste O . Clinical heterogeneity and outcomes of antisynthetase syndrome[J]．Curr Rheumatol Rep, 2013，15(8)：349. DOI: 10.1007/s11926-013-0349-8 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Mahler M , Miller FW , Fritzler MJ . Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review[J]．Autoimmun Rev, 2014，13(4-5)：367-371. DOI: 10.1016/j.autrev.2014.01.022 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Aggarwal R , Cassidy E , Fertig N ,et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients[J]．Ann Rheum Dis, 2014，73(1)：227-232. DOI: 10.1136/annrheumdis-2012-201800 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Rojas-Serrano J , Herrera-Bringas D , Mejía M ,et al. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)[J]．Clin Rheumatol, 2015，34(9)：1563-1569. DOI: 10.1007/s10067-015-3023-x .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Hamaguchi Y , Fujimoto M , Matsushita T ,et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome[J]．PLoS One, 2013，8(4)：e60442. DOI: 10.1371/journal.pone.0060442 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Lega JC , Fabien N , Reynaud Q ,et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome[J]．Autoimmun Rev, 2014，13(9)：883-891. DOI: 10.1016/j.autrev.2014.03.004 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Hozumi H , Enomoto N , Kono M ,et al. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study[J]．PLoS One, 2015，10(3)：e0120313. DOI: 10.1371/journal.pone.0120313 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Kawasumi H , Gono T , Kawaguchi Y ,et al. Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies[J]．Clin Med Insights Circ Respir Pulm Med, 2015，9(Suppl 1)：9-17. DOI: 10.4137/CCRPM.S23313 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Yoshifuji H . Biomarkers and Autoantibodies of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies[J]．Clin Med Insights Circ Respir Pulm Med, 2015，9(Suppl 1)：141-146. DOI: 10.4137/CCRPM.S36748 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Sato S , Kuwana M , Fujita T ,et al. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease[J]．Mod Rheumatol, 2013，23(3)：496-502. DOI: 10.1007/s10165-012-0663-4 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Zou J , Guo Q , Chi J ,et al. HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients[J]．Clin Rheumatol, 2015，34(4)：707-714. DOI: 10.1007/s10067-015-2866-5 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Horai Y , Koga T , Fujikawa K ,et al. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis[J]．Mod Rheumatol， 2015，25(1)：85-89. DOI: 10.3109/14397595.2014.900843 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Kobayashi N , Takezaki S , Kobayashi I ,et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis[J]．Rheumatology (Oxford), 2015，54(5)：784-791. DOI: 10.1093/rheumatology/keu385 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Xu Y , Yang CS , Li YJ ,et al. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis[J]．Clin Rheumatol, 2016，35(1)：113-116. DOI: 10.1007/s10067-015-3139-z .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Hozumi H , Fujisawa T , Nakashima R ,et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease[J]．Respir Med, 2016，121：91-99. DOI: 10.1016/j.rmed.2016.10.019 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Oddis CV . Update on the pharmacological treatment of adult myositis[J]．J Intern Med, 2016，280(1)：63-74. DOI: 10.1111/joim.12511 .
返回引文位置Google Scholar
百度学术
万方数据
[26]
Moghadam-Kia S , Aggarwal R , Oddis CV . Treatment of inflammatory myopathy: emerging therapies and therapeutic targets[J]．Expert Rev Clin Immunol, 2015，11(11)：1265-1275. DOI: 10.1586/1744666X.2015.1082908 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Witt LJ , Curran JJ , Strek ME . The Diagnosis and Treatment of Antisynthetase Syndrome[J]．Clin Pulm Med, 2016，23(5)：218-226. DOI: 10.1097/CPM.0000000000000171 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
徐作军，Email: mocdef.labiamtohjzux
B
科技部国家重点研发计划精准医学研究重点项目 (2016YFC0905700)
中央高校基本科研业务费专项资金和协和青年基金 (3332016003)
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大